Patients with colorectal adenoma polyps (PLPs) are at higher risk for developing colorectal cancer (CRC). However, the development of improved and robust biomarkers to enable the screening, surveillance, and early detection of PLPs and CRC continues to be a challenge. The aim of this study was to identify biomarkers of progression to CRC through metabolomic profiling of human serum samples with a multistage approach. METHODS: Metabolomic profiling was conducted with the Metabolon platform for 30 CRC patients, 30 PLP patients, and 30 control subjects, and this was followed by the targeted validation of the top metabolites in an additional set of 50 CRC patients, 50 PLP patients, and 50 controls with liquid chromatography-tandem mass spectrometry. Unconditional multivariate logistic regression models, adjusted for covariates, were used to evaluate associations with PLP and CRC risk. RESULTS: For the discovery phase, 404 serum metabolites were detected, with 50 metabolites showing differential levels between CRC patients, PLP patients, and controls (P for trend < .05). After validation, the 3 top metabolites (xanthine, hypoxanthine, and D-mannose) were validated: lower levels of xanthine and hypoxanthine and higher levels of D-mannose were found in PLP and CRC cases versus controls. A further exploratory analysis of metabolic pathways revealed key roles for the urea cycle and caffeine metabolism associated with PLP and CRC risk. In addition, a joint effect of the top metabolites with smoking and a significant interaction with the body mass index were observed. An analysis of the ratio of hypoxanthine levels to xanthine levels indicated an association with CRC progression. CONCLUSIONS: These results suggest the potential utility of circulating metabolites as novel biomarkers for the early detection of CRC. Cancer 2017;123:4066-74.
INTRODUCTION
Colorectal cancer (CRC) is one of the most prevalent and deadly types of cancer worldwide and is a major cause of human morbidity and mortality. 1 As the third most common type of cancer in the United States according to the American Cancer Society, CRC has been estimated to be responsible for more than 136,000 new cases and 50,000 deaths in 2015. 2 Several preventive screening and detection methods, including the fecal occult blood test, the fecal immunochemical test, colonoscopy, sigmoidoscopy, and a family history-based risk assessment, have been suggested for CRC. 3 The development of improved and robust biomarkers to enable the screening, surveillance, and early detection of CRC continues to be a challenge. Patients with colorectal adenoma polyps (PLPs) are at higher risk for developing colon cancer; however, noninvasive methods for identifying these patients with high sensitivity and specificity are not clinically available. Studies describing molecular phenotypes of patients with CRC and PLPs can improve the understanding of the pathophysiology of CRC and offer strategies for monitoring the population at risk for CRC.
Serum metabolites are emerging as promising minimally invasive biomarkers for the early detection and prognostication of cancers. Metabolomics, one of the omic sciences in systems biology, is the global assessment of endogenous smallmolecule biochemicals (metabolites) within a biological system; it provides advanced methods for identifying changing metabolisms and, in particular, metabolite levels, and this has resulted in rapid progress in disease biomarker discovery over the past decade. 4 Perturbations in important metabolic pathways have, therefore, been the focus of many cancer studies. 5 Numerous studies have profiled the circulating or tissue metabolites in CRC patients to identify markers for prognosis, cancer progression monitoring, and early cancer screening and detection. [6] [7] [8] [9] However, only a few studies have focused on identifying metabolite biomarkers for PLP patients. For example, Daniel Raftery's group has investigated serum metabolic profile differences between colorectal polyp patients and healthy controls. 10 The aim of this study was to identify circulating biomarkers of CRC disease progression through the metabolomic profiling of human serum samples with a 2-step global and targeted approach involving both discovery and validation phases, which may offer new avenues for risk prediction and early disease detection.
MATERIALS AND METHODS

Patient Population and Study Design
This was a retrospective project including 2 phases of case-control pairs, which included 30 healthy controls, 30 PLP patients, and 30 CRC patients for metabolomic profile screening in the discovery phase and 50 healthy controls, 50 PLP patients, and 50 CRC patients in the validation phase. The PLP and CRC patients had no prior chemotherapy or radiotherapy treatment, and they were histologically confirmed and recruited at The University of Texas MD Anderson Cancer Center between 2006 and 2013. In parallel, healthy individuals were recruited from the general population with no cancer history except for nonmelanoma skin cancer, and they were matched to cases by sex, age (65 years), ethnicity, and residence. The random-digit dialing method was used to identify and recruit controls. The body mass index (BMI) was classified in accordance with the World Health Organization standard classification (normal BMI < 25 kg/m 2 ; overweight BMI 25 kg/m 2 ). Individuals who never smoked or smoked fewer than 100 cigarettes in their lifetime were identified as never smokers. Individuals who smoked at least 100 cigarettes in their lifetime were considered ever smokers. The lifestyle and demographic information for the cases and controls was collected from the same selfadministered questionnaire, and all study participants signed an informed consent form according to institutional guidelines. This study was approved by the institutional review board of The University of Texas MD Anderson Cancer Center.
Global Metabolomic Profiling and Individual Targeted Metabolite Validation
A more detailed description can be found in the online supporting information. In brief, blood samples were collected from patients and healthy controls. Whole blood specimens were immediately processed to obtain the serum fraction and were stored at 2808C until retrieval. All serum samples were thawed on ice before the experiment. The metabolite detection was separated into a discovery phase, which involved global metabolomic profiling, and a validation phase, which measured candidate compounds from the discovery phase. Global metabolomics was performed by Metabolon (Durham, North Carolina) with 200 lL of serum as previously described.
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The validation experiments were conducted with a liquid chromatography-tandem mass spectrometry (LC-MS/ MS) platform and 100-lL serum samples at Texas Southern University. The LC-MS/MS assays met the standards of the Food and Drug Administration as indicated by Guidance for Industry: Bioanalytical Method Validation.
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Absolute concentrations were determined as micrograms per milliliter or nanograms per microliter. We chose 3 of the top metabolites with altered trends in the global metabolic profiling phase for analysis by targeted detection in the validation phase on the basis of biological relevance, significant expression levels, and assay availability.
Pathway Analyses
The Kyoto Encyclopedia of Genes and Genomes database was used to identify the pathways of differential metabolites. 13 We identified the metabolic maps of significant CRC metabolites by using their Kyoto Encyclopedia of Genes and Genomes compound identifiers. MetaboAnalyst 3.0, a comprehensive bioinformatic tool for examining the relations between the identified metabolites and their corresponding mapped genes and pathways, was used to observe the general biological processes in PLPs and CRC (http://www.metaboanalyst.ca/). 14 
Statistical Methods
All statistical analyses were undertaken with Stata software (version 10.1; StataCorp, College Station, Texas). We compared the differences between population subgroups with the Pearson chi-square test for categorical variables, whereas the Student t test was used for continuous variables in both the discovery and validation phases. The data of the discovery set, generated by the Metabolon platform, were log 2 -transformed. During quality control, metabolites for which more than 20% of the samples had undetectable expression were removed. A comparison of overall mean values for metabolites between different groups of subjects was analyzed with the Wilcoxon ranksum test. We assessed individual metabolites as categorical variables by setting the cutoff points as the median values for the control group and dichotomizing all cases into high-and low-risk groups. We modeled the associations between xanthine, hypoxanthine, and D-mannose and the CRC progression risk by conducting logistic regression models. The odds ratio (OR) and the corresponding 95% confidence interval (CI) were calculated with unconditional multivariate logistic regression models, which were adjusted for age, sex, smoking status, BMI, and batch effect. Because smoking and BMI may influence the CRC risk and metabolism, we added the interaction factors for smoking and BMI to the multivariate models to determine the interaction between the metabolite level, BMI, and smoking in modulating CRC risk. All statistical tests were 2-sided with the significance set at P < .05.
RESULTS
Population Characteristics
The study population comprised 80 CRC patients, 80 PLP patients, and 80 control subjects who did not have a prior history of cancer. Table 1 presents the demographic characteristics of the 3 groups in both the discovery phase and the validation phase, including sex, age, mean population BMI value, smoking status, and BMI group (overweight and normal categories). The mean ages of CRC, PLP, and control individuals were 53.97, 51.87, and 55.23 years, respectively, in the discovery phase and 58.66, 57.72 and 57.92 years, respectively, in the validation phase. There were no significant differences between the 3 groups in the variables of sex, age, and BMI value in either the discovery set or the validation set. However, the overweight population (BMI 25 kg/m 2 ) in the CRC and PLP groups was proportionally significantly higher than the overweight population in the control group (73.91% vs 67.86% vs 50% in the discovery set and 84.09% vs 62.86% vs 50% in the validation set).
Metabolites Differentially Expressed in the Discovery Phase and Mapped in the Pathway Analysis
We used the Metabolon metabolomic profiling platform to identify 404 metabolites in serum samples from matched CRC patients (n 5 30), PLP patients (n 5 30), and healthy control subjects (n 5 30) in the discovery phase (Table 1) . Before the statistical analysis, we performed quality control to exclude metabolites with values missing for more than 20% of the samples (Supporting Fig. 1 [see online supporting information]). Among the 301 remaining metabolites, 50 compounds displayed a significant trend of differential expression between CRC patients, PLP patients, and controls according to a Wilcoxon rank-sum test analysis. Twenty metabolites showed increasing levels in CRC and PLP patients in comparison with controls, and 30 metabolites had decreasing levels (Supporting Table 1 [see online supporting information]). Table 2 displays the top 10 metabolites with differential levels between controls, PLP patients, and CRC patients.
To probe the biological relevance of these metabolites, the global metabolite pathways were analyzed. There were 32 subpathways identified from the significant metabolites (Supporting Table 2 [see online supporting information]). Further analysis indicated that the differential metabolites were mapped to 5 superpathways that characterized homeostasis metabolism activity in protein biosynthesis, purine metabolism, and energy. Notably, the result pointed to the urea cycle and caffeine metabolism as the main differential pathways in CRC Metabolites showing a significant trend in serum levels between controls and PLP and CRC patients could be potential biomarkers for the early detection of malignant colorectal disease. Of the 65 promising biomarkers, we chose the top 3 metabolites-xanthine, hypoxanthine, and D-mannose-for further validation, according to their statistical significance as well as scientific impact from the previous literature, by performing standard LC/ MS-MS assays. One of the top metabolites was a small peptide that was not officially multiplexed in the Metabolon platform; therefore, we removed it from further consideration (Table 2) . We measured the levels of selected metabolites in a group of participants in the validation phase, which consisted of 50 healthy individuals, 50 PLP patients, and 50 CRC patients ( Table 1 ). The expression levels of these compounds all exhibited significant trends between controls and PLP and CRC patients in both the discovery and validation sets (P < .01; Fig. 1 ). In the validation phase, levels of xanthine and hypoxanthine in CRC and PLP patients were lower than those in controls, whereas D-mannose in the CRC and PLP groups displayed higher levels in comparison with controls (P < .01); this was consistent with the discovery set. We also conducted stratified analyses by sex, age, smoking status, and BMI (Supporting Table 4 [see online supporting information]) to determine whether these host factors influenced metabolite levels in the cases and controls. In general, no dramatic changes were seen; however, the differential effects were more significant in ever smokers, younger subjects, and overweight/obese subjects.
Associations of Xanthine, Hypoxanthine, and D-Mannose With PLP and CRC Risk
The differential levels of xanthine, hypoxanthine, and Dmannose prompted us to examine the association of these metabolites with PLP and CRC risk. We dichotomized the case levels of metabolites on the basis of median levels in controls. As shown in Table 3 , lower levels of xanthine and hypoxanthine were associated with higher risks of PLPs and CRC in both the discovery and validation sets (OR range, 1.8-38.8). In contrast, a higher level of Dmannose was associated with increased risks of PLPs and CRC (OR range, [8] [9] [10] [11] [12] [13] [14] [15] [16] . Some association analyses could not be performed because of the absence of subjects in the subgroups.
Joint Effects With Smoking and BMI
Previous studies have revealed that obesity and smoking are risk factors for CRC. We analyzed the joint effects of the 3 metabolic markers with smoking and BMI on PLP and CRC risk in the validation set. The results indicated that in ever smokers, a low level of xanthine and a low level of hypoxanthine had a joint effect with smoking on the PLP risk (OR for xanthine, 12.46; 95% CI, 2.04-75.95; P < .01; OR for hypoxanthine, 7.27; 95% CI, 1.57-33.68; P 5 .01; Supporting 3.94-217.01; P < .01; OR for hypoxanthine, 14.20; 95% CI, 1.39-84.26; P < .01). We also found that overweight/ obese subjects (BMI 25 kg/m 2 ) with a low level of xanthine or hypoxanthine had an elevated PLP risk (OR for xanthine, 19.1; 95% CI, 1.98-185; P < .05; OR for hypoxanthine, 10.1; 95% CI, 1.78-57.5; P < .01; Supporting Table 6 [see online supporting information]). High levels of D-mannose showed joint effects with smoking on the CRC risk (OR, 27.91; 95% CI, 2.98-261.33; P < .01; Supporting Tables 5). Notably, there was a significant interaction between the BMI and the D-mannose level in modifying CRC risk (P for interaction < .001; Supporting Table 6 ).
Effects of the Hypoxanthine/Xanthine Ratio on PLP and CRC Risk
Hypoxanthine and xanthine are metabolites found in the same biological pathway involving purine metabolism, and low levels of these metabolites increased the risk for PLPs and CRC. To evaluate the potential effects of both metabolites on susceptibility to PLPs and CRC, we combined the 2 markers by analyzing the association of the hypoxanthine/xanthine ratio (purine metabolite ratio) with PLP and CRC risk via the unconditional multivariate logistic regression analysis method. Figure 2 demonstrates the association of the purine metabolite ratio with the risks of PLPs, CRC, and CRC progression. In comparison with controls, 96% of PLP cases and 90% of CRC cases displayed low ratios. A low purine metabolite ratio was associated with an increased PLP risk (OR, 22.08; 95% CI, 4.18-116.41; P < .001). A similar effect was also seen with a low ratio and an elevated risk of CRC (OR, 15.38; 95% CI, 3.94-60.00; P < .001) and CRC progression (OR, 13.73; 95% CI, 4.64-40.59; P < .001). We also explored the joint effect of the smoking status, BMI, and purine metabolite ratio on PLP and CRC risk Figure 1 . Levels of validated serum metabolites showing differential levels in the discovery and validation groups. The box plots display the median levels of xanthine, hypoxanthine, and D-mannose for the CRC, PLP, and CTRL groups in both the discovery and validation phases. The line in the middle of each box indicates the median value, and the box defines values from the 25th percentile to the 75th percentile. The upper and lower bars mark the boundaries of metabolite levels within the 95% confidence interval. P values were generated from the Wilcoxon rank-sum test. CRC indicates colorectal cancer; CTRL, control; PLP, adenoma polyp.
in the validation set (table not shown). Smoking could result in increasing PLP and CRC risk for subjects with low ratios (OR for PLP risk, 17.31; 95% CI, 2.57-108.92; P < .001; OR for CRC risk, 15.30; 95% CI, 2.56-91.39; P < .001). In addition, overweight/obese patients with a low ratio showed a high PLP risk (OR, 24.04; 95% CI, 2.59-222.77; P < .01). Moreover, the BMI and the metabolite ratio displayed a significant interaction effect on the CRC risk (P < .001).
DISCUSSION
Dysregulation of the metabolic pathways has been implicated in neoplastic development and is characterized as a hallmark of cancer. 15 Tumor cells require large quantities of different energy sources to support their high rate of proliferation with increased energy consumption, and this leads to alterations of key metabolic pathways. 16 In this study, we aimed to identify and validate serum metabolite biomarkers for the noninvasive early detection of colorectal polyps and cancer and as risk factors for cancer progression on the basis of a 2-phase approach using independent detection platforms. Our findings showed that 50 metabolites were significantly altered in PLP and CRC patients in the discovery phase with metabolomic profiling; they were mapped to 8 superpathways (nucleotide, carbohydrate, peptide, amino acid, lipid, energy, carnitine metabolism, and xenobiotic pathways) and 31 subpathways (Supporting Table 2 [see online supporting information]) associated with metabolism. The sample size was increased in the validation phase to verify the candidate metabolites as predictors of PLP and CRC risk. Specifically, we found significantly altered expression of xanthine, hypoxanthine, and D-mannose in both the discovery and validation sets. In addition, smoking and obesity, which are known risk factors for CRC, were found to modify the association with PLP and CRC risk.
To our knowledge, few studies have investigated metabolite shifts in CRC development. 8 In the current study, we observed a variety of serum metabolites with altered levels in PLP and CRC subjects, which suggested a stepwise progression. Notably, we observed that 2 metabolites of the purine metabolism pathway, xanthine and hypoxanthine, were associated with PLP and CRC risk.
Xanthine is a metabolite intermediate in the degradation of adenosine monophosphate to uric acid, whereas hypoxanthine is oxidized to xanthine by xanthine oxidase, a form of xanthine oxidoreductase 17 (Supporting Fig. 3 [see online supporting information]). Xanthine oxidase is the last catalyzing enzyme of purine metabolism, so it plays a critical role in nucleic acid degradation. Cancer and polyps are often accompanied by low expression levels of xanthine and hypoxanthine, likely because of increased DNA synthesis (adenine utilization) in the hyperproliferative tissues. Xanthine can be produced by all human cells as well as specific plants and animals. Interestingly, caffeine is one of several types of xanthine derivatives and may affect circulating xanthine levels. Indeed, a pathway analysis of metabolites indicated that compounds of caffeine metabolism differed significantly between controls and PLP and CRC patients. Some studies have reported that caffeine inhibits colon cancer cell proliferation and reduces CRC risk. 18, 19 Decreased hypoxanthine levels were detected in the urine of patients with non-Hodgkin lymphoma, 20 and the same trend of reduced levels was observed in gastric cancer patients versus normal individuals. 21 The hypoxanthine level was reduced in the serum samples of advanced rectal cancer patients when it was compared between different stages of tumor progression, 22 and this is consistent with our findings. Lower levels of xanthine were identified in glioblastoma cases versus controls in a study by Bjorkblom et al. 23 Because uric acid is the termination product of xanthine and hypoxanthine degradation, its level is affected by xanthine and hypoxanthine levels (Supporting Fig. 3) . Findings from previous studies have raised the idea that uric acid might contribute to cancer risk, recurrence, and mortality, 24 and this points to the importance of this metabolic pathway in influencing neoplastic development and outcomes.
We also analyzed a novel measure, the hypoxanthine/xanthine ratio. This is the first study to report an association of the hypoxanthine/xanthine ratio with PLP and CRC risk. Because xanthine is converted from hypoxanthine, its level is dependent on the activity of hypoxanthine metabolism. Thus, the hypoxanthine/xanthine ratio demonstrates the relative metabolic rate of hypoxanthine and xanthine degradation. In our study, a low ratio was associated with increased risk, and this suggests that PLP and CRC patients have higher hypoxanthine turnover, likely because of elevated xanthine oxidase activity. Our findings are consistent with the previous study by Linder et al, 25 who indicated that the expression of xanthine oxidase was elevated during the progression of human colon carcinoma cells in in vitro experiments. The circulating xanthine oxidase level has also been reported to be higher in head and neck carcinoma patients 26 as well as lung cancer patients, 27 and its activity has been observed to be significantly increased in human cancerous colorectal tissues versus noncancerous adjacent tissues. 28 In contrast to the decrease in xanthine and hypoxanthine levels associated with increased PLP and CRC risk, a low D-mannose level was protective in our study. The early literature reported that high mannose oligosaccharides were more prevalent on tumor cell surfaces than normal cells. 29 Mannose, an intermediate metabolite of the galactose metabolism pathway, plays an essential role in N-linked glycosylation, which modifies certain proteins at the posttranslational step. It has been reported that high mannose glycans are increased in breast cancer progression, 30 and glycans take part in dominant cancer progression phases such as cancer cell proliferative signaling, the activation of invasion and metastasis, and tumorpromoting inflammation. 31 Our previous study observed that D-mannose was elevated in late-stage esophageal cancer patients, 32 and this is consistent with the finding of higher levels of D-mannose in PLP and CRC cases versus controls.
Another discovery of our current study is the joint effect of the metabolites, BMI, and smoking status on the CRC and PLP risk. It is known that smoking and obesity are risk factors for CRC. [32] [33] [34] [35] We observed that in ever smokers, the risk of PLPs and CRC significantly increased (approximately 2-to 3-fold) in subjects with low xanthine or hypoxanthine levels or high D-mannose levels in comparison with never smokers. A similar joint effect was seen with a high BMI modifying the risk of PLPs in subjects with low xanthine or hypoxanthine levels or high D-mannose levels in comparison with low-BMI individuals. It is notable that in the BMI analysis, there was a significant interaction with D-mannose in modifying the CRC risk. One limitation of these analyses is that we were able to analyze only the validation set because of the limited sample size of the discovery group. Moreover, the usage of different metabolic profiling platforms precluded us from pooling the 2 sets of data for a combined analysis. Nevertheless, these partial data may suggest the importance of linking lifestyle factors with specific metabolites in predicting the risk of PLPs and CRC.
Original Article
Besides the small sample size, which might have conferred low statistical power for a subgroup analysis, other potential limitations included the retrospective nature of the study, which allowed the possibility of a recall bias and reverse causation. It should be cautioned that the circulating level of hypoxanthine has been found to correlate with increased blood sample storage time at room temperature. 36 Thus, the metabolite may represent a good biomarker for sample quality. Because our samples from cases and controls were collected and immediately processed in a similar manner and time frame by laboratory personnel without knowledge of the case-control status, any confounding effect from the time of sample storage may be negligible. Moreover, the small fold changes in metabolite levels between patients and controls may present challenges for translational application. Several demographic and personal factors such as sex, age, BMI, diet, and smoking status might influence the metabolomic landscape. Therefore, careful matching of known risk factors during the study design and adjustments of covariates in the statistical analysis are necessary to minimize false discoveries. Nevertheless, the global profiling of circulating metabolites with targeted validation and the comprehensive collection of epidemiological information in a specialty hospital setting provide valuable resources for identifying candidate metabolic biomarkers for clinical applications.
In conclusion, our results support the notion that serum metabolic detection might be used as a noninvasive approach for assessing the risk of CRC progression. We have determined that the analysis of circulating xanthine, hypoxanthine, and D-mannose levels has the potential to distinguish patients with PLPs and CRC from those without cancer. The hypoxanthine/xanthine ratio, which has shown plausible biological and clinical significance, may provide a new assessment tool for gauging the clinical risk of CRC progression. In addition, the analyses of lifestyle factors contributing to the effects of serum metabolites and PLP and CRC risk suggest that smoking and obesity might jointly affect cancer progression by altering metabolic pathways. Taken together, global metabolic changes that are measurable in blood samples might present early indications of CRC development, which could be leveraged as a clinical screening tool to enhance the current diagnostic method. Future prospective validation in independent cohorts is warranted to confirm our observations, and further investigation is needed to determine the potential clinical utility of these findings. 
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